logo
logo

Kyverna Therapeutics Appoints Marc Grasso As Chief Financial Officer

Jun 30, 2025•about 1 month ago

Position

Chief Financial Officer

Company

Kyverna Therapeutics

Marc Grasso
EmeryvilleBiotechnologyHealth Care

Description

Kyverna Therapeutics, Inc has announced the appointment of Dr Marc Grasso as its Chief Financial Officer, effective today. Dr Grasso brings over 25 years of experience in public companies and capital markets.

Company Information

Company

Kyverna Therapeutics

Location

Emeryville, California, United States

About

Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our lead product candidate, KYV-101 is advancing through clinical development across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for stiff-person syndrome, multiple sclerosis and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center, open-label Phase 1/2 trials in the United States and Germany for patients with lupus nephritis.

Related People

Sign in to view contact details

Sign in to view contact details

Sign in to view contact details

Executive Insights

Based on hiring data
New executive impact window
87% of new executives make significant technology decisions within first 100 days
Budget influence
C-level executives control 73% of technology spending decisions
Transformation catalyst
65% of new senior hires launch digital transformation initiatives
Vendor review timeline
New executives typically review existing vendors within 6 months